Seminars in Oncology
Volume 33, Supplement 12 , Pages 3-7, December 2006

Clinical Efficacy Supporting the Role of Intraperitoneal Drug Delivery in the Primary Chemotherapeutic Management of Small-Volume Residual Advanced Ovarian Cancer

  • Maurie Markman

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Maurie Markman, MD, Gynecologic Oncology, The University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030.

The University of Texas, M. D. Anderson Cancer Center, Houston, TX.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This activity is supported by an unrestricted educational grant from MedImmune Oncology, Inc, a subsidiary of MedImmune, Inc.

PII: S0093-7754(06)00424-6

doi:10.1053/j.seminoncol.2006.11.002

Seminars in Oncology
Volume 33, Supplement 12 , Pages 3-7, December 2006

Article Tools